ImmunoBiology partners with CPI to manufacture heat-stabilised PnuBioVax formulation for LMIC use
ImmBio today announced a partnership with CPI, Darlington, to develop a heat-stabilised formulation for PnuBioVax, ImmBio’s multi-antigen vaccine candidate against Pneumococcal diseases. This will eliminate the requirement for a costly and complex cold chain, helping to reduce the cost of the vaccine and increase accessibility in LMICs (Low and Middle Income Countries) where cold chains may be lacking. https://www.uk-cpi.com/news/cpi-partners-with-immunobiology-ltd-to-manufacture-heat-stabilised-pneumococcal-vaccine-formulation... Read more